The great pivot to AI compute, and a mid-cap identity crisisGlobal Report·Jul 22 at 04:17 AM026610.00%01070-1.73%
Zhaoke Ophthalmology says Macau regulator approves presbyopia eye drop YUVEZZIPUBT·Jul 19 at 11:02 PM06622-3.13%
CICC's Mega-Merger Moves Forward While Sinotruk Hits the Gas on EV ExportsGlobal Report·Jul 19 at 04:12 AM01066+1.47%03908+0.28%
Zhaoke Ophthalmology Wins Boao Approval for First Innovative Presbyopia Drug in ChinaTip Ranks·Jul 6 at 11:07 PM06622-3.13%
Kingmaker Footwear files HKEX next-day disclosure return on share repurchase for cancellationPUBT·Jul 6 at 05:03 AM01170-2.22%
Zhaoke Ophthalmology files HKEX next-day disclosure return on share repurchase for cancellationPUBT·Jul 2 at 07:58 PM06622-3.13%
Zhaoke Ophthalmology files HKEX next-day return disclosing share repurchase for cancellationPUBT·Jun 23 at 07:47 PM06622-3.13%
Zhaoke Ophthalmology files HKEX next-day disclosure return on share repurchase for cancellation at HKD 2.54-2.54PUBT·Jun 22 at 08:00 PM06622-3.13%
Zhaoke Ophthalmology’s Myopia Drug NVK002 Accepted for Australian TGA EvaluationTip Ranks·Jun 14 at 11:38 PM06622-3.13%
Zhaoke Ophthalmology Shareholders Approve All Resolutions at 2026 AGMTip Ranks·May 15 at 08:44 AM06622-3.13%
Looking for overseas growth, Aier Eye seeks Hong Kong listingBambooWorks·Apr 30 at 07:50 AM300015+2.37%06622-3.13%
Aier plans to go public in Hong Kong. Can overseas expansion support the new valuation of "eye king"?BambooWorks·Apr 29 at 08:01 PM300015+2.37%02219+2.31%
ZHAOKE OPHTH (6622) expects three products to be approved successively this yearTasty Money·Apr 2 at 02:32 AM06622-3.13%
